journal article·2023-04

A pH‐Activatable Copper‐Biomineralized Proenzyme for Synergistic Chemodynamic/Chemo‐Immunotherapy against Aggressive Cancers

Ting Li, Ying Zhang, Jie Zhu, Fangrui Zhang, An'an Xu, Tian Zhou, Yaoqi Li, Ming Liu, Hengte Ke, Tao Yang, Yong'an Tang, Jing Tao, Liyan Miao, Yibin Deng, Huabing Chen

Advanced Materials· Volume 35· Issue 14
Publisher page

Abstract

Abstract Artificial enzymes have demonstrated therapeutic benefits against diverse malignant tumors, yet their antitumor potencies are still severely compromised by non‐selective catalysis, low atomic‐utilization efficiency, and undesired off‐target toxicity. Herein, it is reported that peroxidase‐like biomineralized copper (II) carbonate hydroxide nanocrystals inside single albumin nanocages (CuCH‐NCs) act as a pH‐activatable proenzyme to achieve tumor‐selective and synergistic chemodynamic/chemo‐immunotherapy against aggressive triple‐negative breast cancers (TNBCs). These CuCH‐NCs show pH‐sensitive Cu 2+ release, which spontaneously undergoes glutathione (GSH)‐mediated reduction into Cu + species for catalyzing the evolution of H 2 O 2 into hydroxyl radicals (·OH) in a single‐atom‐like manner to cause chemodynamic cell injury, and simultaneously activates non‐toxic disulfiram to cytotoxic complex for yielding selective chemotherapeutic damage via blocking cell proliferation and amplifying cell apoptosis. CuCH‐NCs exhibit considerable tumor‐targeting capacity with deep penetration depth, thus affording preferable efficacy against orthotopic breast tumors through synergistic chemodynamic/chemotherapy, together with good in vivo safety. Moreover, CuCH‐NCs arouse distinct immunogenic cell death effect and upregulate PD‐L1 expression upon disulfiram combination, and thus synergize with anti‐PD‐L1 antibody to activate adaptive and innate immunities, together with relieving immunosuppression, finally yielding potent antitumor efficacy against both primary and metastatic TNBCs. These results provide insights into smart and high‐performance proenzymes for synergistic therapy against aggressive cancers.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Nanocluster Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences Soochow University Suzhou 215123 China

Department of Pharmacy The First Affiliated Hospital of Soochow University Suzhou 215006 China

Institute for Interdisciplinary Drug Research and Translational Sciences Soochow University Suzhou 215006 China

State Key Laboratory of Radiation Medicine and Protection and School of Radiation Medicine and Protection Soochow University Suzhou 215123 China

Funding

National Natural Science Foundation of China · Priority Academic Program Development of Jiangsu Higher Education Institutions

References (49)

Show source-provided references
1. 10.1039/C8CS00718G10.1039/C8CS00718G ↗
2. 10.1039/C8CS00457A10.1039/C8CS00457A ↗
3. 10.1021/acs.accounts.9b0014010.1021/acs.accounts.9b00140 ↗
4. 10.1021/acs.chemrev.8b0067210.1021/acs.chemrev.8b00672 ↗
5. 10.1038/nnano.2007.26010.1038/nnano.2007.260 ↗
6. 10.1002/anie.20190475110.1002/anie.201904751 ↗
7. 10.1021/jacs.9b1287310.1021/jacs.9b12873 ↗
8. 10.1038/s41467-018-05798-x10.1038/s41467-018-05798-x ↗
9. 10.1002/adma.20190288510.1002/adma.201902885 ↗
10. 10.1002/anie.20191614210.1002/anie.201916142 ↗
11. 10.1038/s41467-019-14199-710.1038/s41467-019-14199-7 ↗
12. 10.1002/anie.20200886810.1002/anie.202008868 ↗
13. 10.1039/B312445B10.1039/B312445B ↗
14. 10.1016/j.cej.2016.11.01610.1016/j.cej.2016.11.016 ↗
15. 10.1021/jacs.8b0871410.1021/jacs.8b08714 ↗
16. 10.1021/jacs.9b0345710.1021/jacs.9b03457 ↗
17. 10.1038/s41467-020-16513-010.1038/s41467-020-16513-0 ↗
18. 10.1002/anie.20160550910.1002/anie.201605509 ↗
19. 10.1016/j.tiv.2015.03.02010.1016/j.tiv.2015.03.020 ↗
20. 10.1007/s00204-014-1355-y10.1007/s00204-014-1355-y ↗
21. 10.1002/adma.20200689210.1002/adma.202006892 ↗
22. 10.1021/acsnano.7b0423010.1021/acsnano.7b04230 ↗
23. 10.1038/s41596-018-0001-110.1038/s41596-018-0001-1 ↗
24. 10.1074/jbc.M60958220010.1074/jbc.M609582200 ↗
25. 10.1038/s41598-021-85107-710.1038/s41598-021-85107-7 ↗
26. 10.1096/fj.201701157R10.1096/fj.201701157R ↗
27. 10.1038/s41467-021-22111-510.1038/s41467-021-22111-5 ↗
28. 10.1038/s41598-017-11480-x10.1038/s41598-017-11480-x ↗
29. 10.1126/science.abf052910.1126/science.abf0529 ↗
30. 10.1021/acs.nanolett.6b0426910.1021/acs.nanolett.6b04269 ↗
31. 10.1002/anie.20171014410.1002/anie.201710144 ↗
32. 10.1016/j.drudis.2020.04.00310.1016/j.drudis.2020.04.003 ↗
33. 10.1073/pnas.110112610810.1073/pnas.1101126108 ↗
34. 10.1038/s41419-021-03454-910.1038/s41419-021-03454-9 ↗
35. 10.1038/natrevmats.2017.2410.1038/natrevmats.2017.24 ↗
36. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
37. 10.1016/j.jconrel.2020.10.03010.1016/j.jconrel.2020.10.030 ↗
38. 10.1016/j.biomaterials.2014.03.08410.1016/j.biomaterials.2014.03.084 ↗
39. 10.1021/acs.bioconjchem.0c0020910.1021/acs.bioconjchem.0c00209 ↗
40. 10.1126/science.aar406010.1126/science.aar4060 ↗
41. 10.1038/nrc.2016.3610.1038/nrc.2016.36 ↗
42. 10.1158/1078-0432.CCR-16-300110.1158/1078-0432.CCR-16-3001 ↗
43. 10.3389/fonc.2021.73485310.3389/fonc.2021.734853 ↗
44. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
45. 10.1038/nrc338010.1038/nrc3380 ↗
46. 10.3389/fimmu.2018.0305910.3389/fimmu.2018.03059 ↗
47. 10.1002/adma.20210578310.1002/adma.202105783 ↗
48. 10.1038/s41571-019-0308-z10.1038/s41571-019-0308-z ↗
49. 10.1038/s41573-021-00155-y10.1038/s41573-021-00155-y ↗